Status:
COMPLETED
Role of Polymorphisms in the IL-1 Gene Cluster
Lead Sponsor:
Singapore National Eye Centre
Conditions:
Glaucoma
Eligibility:
All Genders
40+ years
Brief Summary
Glaucoma, an optic neuropathy characterized by progressive visual field loss, is the leading cause of irreversible blindness worldwide. The condition has a substantial heritable basis, as illustrated ...
Detailed Description
Aims: Primary objective: To investigate if polymorphisms in the Il-1 gene cluster are protective for glaucoma in Asian populations. Secondary objective: To determine if there are differences in sing...
Eligibility Criteria
Inclusion
- Standardized inclusion criteria for glaucoma will be used, which is the presence of glaucomatous optic neuropathy (defined as loss of neuroretinal rim with a cup:disc ratio of 0.7 or greater) with compatible visual field loss. PACG will be defined as the presence of at least 180 degrees of angle in which the trabecular meshwork is not visible on gonioscopy with the presence of glaucomatous optic neuropathy. POAG patients will have open angles on gonioscopy; POAG patients with a mean IOP without treatment that is consistently less than 21 mm Hg on diurnal testing will be classified as NTG.
- There will be another 100 control patients with no clinical evidence of glaucoma recruited from the general clinics.
Exclusion
- Individuals with secondary angle closure and other ocular diseases will be excluded.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
OBSERVATIONAL
End Date :
June 1 2006
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00346541
Start Date
July 1 2005
End Date
June 1 2006
Last Update
June 30 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Singapore National Eye Centre
Singapore, Singapore, 168751